July 9 (Reuters) - Novartis AG NOVN.S:
SIRONAX: GRANTS NOVARTIS EXCLUSIVE OPTION TO ACQUIRE ITS BRAIN DELIVERY PLATFORM WHILE RETAINING RIGHTS TO ADVANCE SELECTED THERAPEUTIC ASSETS
SIRONAX: SIRONAX IS ELIGIBLE TO RECEIVE UP TO $175 MILLION IN UPFRONT AND NEAR-TERM PAYMENTS UNDER AGREEMENT
SIRONAX: UNDER AGREEMENT, NOVARTIS TO EVALUATE BDM PLATFORM WITHIN OPTION PERIOD